Skip to main content
SpringerLink
Log in

Cancers of the Urinary Tract

  • Chapter
Suki and Massry’s THERAPY OF RENAL DISEASES AND RELATED DISORDERS

  • 294 Accesses

Abstract

In this chapter, we will review the most common malignancies encountered in the urinary tract. Carcinomas of the kidney, bladder, and prostate account for 41% of cancers diagnosed annually in men and 4% in women and for 18% and 3% of cancer deaths, respectively. Dramatic improvements in cancer diagnosis and treatment have taken place in the last decade. A tumor suppressor gene implicated in familial and sporadic renal cell carcinoma has been cloned, and immunotherapy with biologic response modifiers now offers hope to patients with metastatic cancer. Outpatient systemic chemotherapy may help patients with advanced transitional cell carcinoma of the kidney and bladder to live longer. Continent urinary diversion provides significant improvement in quality of life for patients undergoing radical cystectomy. Molecular staging of bladder cancer is now possible with the application of immunohistochemical staining of tissue sections to detect mutations in the p53 tumor suppressor gene. Prostate cancer is now the leading cause of cancer in men over the age of 50 and the second leading cause of cancer death. Prostate-specific antigen and transrectal ultrasound have revolutionized diagnosis and management of localized prostate cancer. As new technology proliferates and our understanding of neoplastic transformation evolves, we are poised to accept the challenge of not only cure of urinary tract cancer but prevention as well.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Grawitz VP: Die sogenannte lipome der niere. Pathol Anat 93: 39–63, 1883.

    Google Scholar 

  2. Makay B, Ordonez NG, Khoursland J: The ultrastructure and immunocytochemistry of renal cell carcinoma. Ultrastruct Pathol 11: 483–502, 1987.

    Article  Google Scholar 

  3. Wallace AC, Nairn RC: Renal tubular antigens in kidney tumors. Cancer 29: 977–981, 1972.

    Article  PubMed  CAS  Google Scholar 

  4. Fromowitz FB, Bard RH: Clinical implications of pathologic subtypes in renal cell carcinoma. Semin Urol 8: 31–50, 1990.

    PubMed  CAS  Google Scholar 

  5. Bennington JL, Laubscher FA: Epidemiologic studies on carcinoma of the kidney. Cancer 21: 1069–1071, 1968.

    Article  PubMed  CAS  Google Scholar 

  6. Johanssen SK: Carcinogenicity of analgesics: long-term treatment of Sprague-Dawley rats with phenacetin, phenazone, caffeine, and paracetamol (acetamidophen). Int J Cancer 27: 521–529, 1981.

    Article  Google Scholar 

  7. Lornoy W, Becaus I, De Vleeschouwer M: Renal cell carcinoma, a new complication of analgesic nephropathy. Lancet 1: 1271–1272, 1986.

    Article  PubMed  CAS  Google Scholar 

  8. McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni JE, Jr: A population-based case-control study of renal cell carcinoma. J Nati Cancer Inst 72: 275–284, 1984.

    CAS  Google Scholar 

  9. Malker HR, Malker BK, McLaughlin JK, Blot WJ: Kidney cancer among leather workers. Lancet 1: 56, 1984.

    Article  PubMed  CAS  Google Scholar 

  10. Kolonel LN: Association of cadmium with renal cancer. Cancer 37: 1782–1787, 1976.

    Article  PubMed  CAS  Google Scholar 

  11. Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE: Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst 77: 351–356, 1986.

    PubMed  CAS  Google Scholar 

  12. Kirkman H, Bacon RL: Renal adenomas and carcinomas in diethylstilbesterol treated male golden hamsters. Anat Rec 103: 475–476, 1949.

    Google Scholar 

  13. Bretan PN Jr, Busch MP, Hricak H, Williams RD: Chronic renal failure: a significant risk factor in the development of acquired renal cysts and renal cell carcinoma. Cancer 57: 1871–1879, 1986.

    Article  PubMed  Google Scholar 

  14. Ishikawa I: Renal cell carcinoma in chronic hemodialysis patients-a 1990 questionnaire study in Japan. Kidney Int 43:S-167-S-169, 1993.

    Google Scholar 

  15. Fallon B, Williams RD: Renal cancer associated with acquired cystic disease of the kidney and chronic renal failure. Semin Urol 7: 228–236, 1989.

    PubMed  CAS  Google Scholar 

  16. Reiter RE, Zbar B, Linehan WM: Molecular genetic studies of renal cell carcinoma: Potential biologic and clinical significance for genitourinary malignancy. In: PC Walsh, AB Retik, TA Stamey, ED Vaughan Jr, eds, Campbell’s Urology, 6th ed, update 7. WB Saunders, Philadelphia, pp 1–15, 1993.

    Google Scholar 

  17. Glenn GM, Choyke PL, Zbar B, Linehan WM: von HippelLindau disease: clinical aspects and molecular genetics. In: EE Anderson, ed, Problems in Urologic Surgery: Benign and Malignant Tumors of the Kidney. JB Lippincott Philadelphia, pp 312–330, 1990.

    Google Scholar 

  18. Latif F, Troy K, Gnarra J: Identification of the von HippelLindau disease tumor suppressor gene. Science 260: 1317 1320, 1993.

    Google Scholar 

  19. Parker SL, Tong T, Bolden S, Wingo PA: Cancer Satistics, 1997. CA 47: 5–27, 1997.

    PubMed  CAS  Google Scholar 

  20. Ries LAG, Hankey BF, Miller BA, Hartman AM, Edwards BK: Cancer Statistics Review 1973–88. National Cancer Institute, NIH Pub. No. 91–2789, 1991.

    Google Scholar 

  21. Castallenos RD, Aron BS, Evans AT: Renal adenocarcinoma in children: incidence therapy, and prognosis. J Urol 111: 534–537, 1974.

    Google Scholar 

  22. Cheng WS, Farrow GM, Zincke H: The incidence of multicentricity in renal cell carcinoma. J Urol 146:1221–1223, 1991.

    Google Scholar 

  23. Mukamel E, Konichersky M, Engelstein D, Servadio C: Incidental small renal tumors accompanying clinically overt renal cell carcinoma. J Urol 140: 22–24, 1988.

    PubMed  CAS  Google Scholar 

  24. Thoenes W, Storkel S, Rumpelt HJ: Histopathology and classification of renal cell tumors (adenomas, oncocytomas, and carcinomas): the basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 181: 125143, 1986.

    Google Scholar 

  25. Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655–663, 1982.

    Article  PubMed  CAS  Google Scholar 

  26. Weiss MA, Mills SE, eds: Genitourinary Tract Pathology. Gower Medical Publishing, New York, 1993.

    Google Scholar 

  27. Aizawa S, Suzuki M, Kikuchi Y, Nikaido T, Matsumoto K: Clinicopathological study on small renal cell carcinomas with metastases. Acta Pathol Jpn 37: 947–954, 1987.

    PubMed  CAS  Google Scholar 

  28. Bell ET: Classification of renal tumors with observations on the frequency of various types. J Urol 39: 238–243, 1938.

    Google Scholar 

  29. Zbar B, Tory K, Merino M, Schmidt L, Glenn G, Choyke P, Walther MW, Lerman M, Linehan WM: Hereditary papillary renal cell carcinoma. J Urol 151: 561–566, 1994.

    PubMed  CAS  Google Scholar 

  30. Lieber MM: Renal oncocytoma: prognosis and treatment. Eur Urol 18 (Suppl 2): 17–21, 1990.

    PubMed  Google Scholar 

  31. Klein MJ, Valensi QJ: Proximal tubular adenomas of kidney with so-called oncocytic features. Cancer 38: 906–914, 1976.

    Article  PubMed  CAS  Google Scholar 

  32. Lieber MM, Tomera KM, Farrow GM: Renal oncocytoma. J Urol 125: 481–485, 1981.

    PubMed  CAS  Google Scholar 

  33. O’Toole KM, Brown M, Hoffman P: Pathology of benign and malignant kidney tumors. Urol Clin North Am 20: 193–206, 1993.

    PubMed  Google Scholar 

  34. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF: Diagnosis and management of renal cell carcinoma-a clinical and pathologic study of 309 cases. Cancer 28: 1165–1177, 1971.

    Article  PubMed  CAS  Google Scholar 

  35. Gelb AB, Shibuya RB, Weis LM, Medeiros LJ: Stage I renal cell carcinoma-a clinicopathologic study of 82 cases. Am J Surg Pathol 17: 275–286, 1993.

    Article  PubMed  CAS  Google Scholar 

  36. Goncharenko V, Gerlock AJ Jr, Kadir S, Turner B: Incidence and distribution of venous extension in 70 hypernephromas. Am J Radiol 133: 263–265, 1979.

    CAS  Google Scholar 

  37. Butler RB, Laucirica R, Scardino PT, Lerner SP: Renal cell carcinoma with inferior vena cava thrombus: common presentation by an uncommon mechanism. Presented at the American Urological Association South Central Section Meeting, Acapulco, Mexico, October 5, 1993.

    Google Scholar 

  38. Skinner DG, Pritchett TR, Lieskovsky G, Boyd SD, Stiles QR: Vena cava involvement by renal cell carcinoma-surgical resection provides meaningful long-term survival. Ann Surg 210: 387–394, 1989.

    Article  PubMed  CAS  Google Scholar 

  39. Marshall FF, Powell KC: Lymphadenectomy for renal cell carcinoma: anatomical and therapeutic considerations. J Urol 128: 677–681, 1982.

    PubMed  CAS  Google Scholar 

  40. Tostain JL, Perraud Y, Gilloz A: Anatomical considerations in lymph node dissection for renal cell carcinoma (abstract 926). J Urol 149: 444A, 1993.

    Google Scholar 

  41. Wood DP Jr: Role of lymphadenectomy in renal cell carcinoma. Urol Clin North Am 18: 421–426, 1991.

    Google Scholar 

  42. Giuliani L, Giberti C, Martorana G, Rovida S: Radical extensive surgery for renal cell carcinoma. J Urol 143: 468–474, 1990.

    PubMed  CAS  Google Scholar 

  43. Bennington JL, Beckwith JB, eds: Tumors of the Kidney, Renal Pelvis, and Ureter. Armed Forces Institute of Pathology, Washington, DC, 1975.

    Google Scholar 

  44. Gibbons RP, Montie JE, Correa RJ Jr, Mason JT: Manifestations of renal cell carcinoma. Urology 8: 201–206, 1976.

    Article  PubMed  CAS  Google Scholar 

  45. Bosniak MA: The current radiologic approach to renal cysts. Radiology 158: 1–10, 1986.

    PubMed  CAS  Google Scholar 

  46. Bosniak MA: Problems in the radiologic diagnosis of renal parenchymal tumors. Urol Clin North Am 20: 217–230, 1993.

    CAS  Google Scholar 

  47. Gottesman JE, Crawford ED, Grossman HB, Scardino PT, McCracken JD: Infarction-nephrectomy for metastatic renal carcinoma-Southwest Oncology Group Study. Urology 25: 248–251, 1985.

    Article  PubMed  CAS  Google Scholar 

  48. Klimberg I, Hunter P, Hawkins IF, Drylie DM, Wajsman Z: Preoperative angioinfarction of localized renal cell carcinoma using absolute ethanol. J Urol 133: 21–24, 1985.

    PubMed  CAS  Google Scholar 

  49. Swanson DA, Johnson DE, Von Eschenbach AC, Chuang VP, Wallace S: Angioinfarction plus nephrectomy for metastatic renal cell carcinoma-an update. J Urol 130: 449–452, 1983.

    PubMed  CAS  Google Scholar 

  50. Robson CJ, Churchill BM, Anderson W: The results of radical nephrectomy for renal cell carcinoma. J Urol 101: 297–301, 1969.

    PubMed  CAS  Google Scholar 

  51. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, eds: Manual for Staging of Cancer. JB Lippincott Company, Philadelphia, 1992.

    Google Scholar 

  52. Esen A, Ozen H, Ayhan A, Ergen A, Tasar C, Remzi F: Serum ferritin: a tumor marker for renal cell carcinoma. J Urol 145: 1134–1137, 1991.

    Google Scholar 

  53. Gingrich JR, Thrasher JB, Paulson DF: Radical nephrectomy for renal cell carcinoma: a contemporary review of presentation, complications and outcome of 356 cases (abstract 932) J Urol 149: 446A, 1993.

    Google Scholar 

  54. Bassil B, Dosoretz DE, Prout GR: Validation of the tumor, nodes and metastases classification of renal cell carcinoma. J Urol 134: 450–454, 1985.

    PubMed  CAS  Google Scholar 

  55. Licht MR, Novick AC: Nephron sparing surgery for renal cell carcinoma. J Urol 149: 1–7, 1993.

    PubMed  CAS  Google Scholar 

  56. Steinbach F, Stockle M, Muller SC, Thuroff JW, Melchior SW, Stein R, Hohenfellner R: Conservative surgery of renal cell tumors in 140 patients: 21 years of experience. J Urol 148: 24–30, 1992.

    PubMed  CAS  Google Scholar 

  57. Licht MR, Novick AC, Goormastic M: Nephron sparing surgery in incidental versus suspected renal cell carcinoma. J Urol 152: 39–42, 1994.

    PubMed  CAS  Google Scholar 

  58. deKernion JB, Belldegrun A: Renal tumors. In: PC Walsh, AB Retik, TA Stamey, ED Vaughan Jr, eds, Campbell’s Urology. WB Saunders, Philadelphia, pp 1053–1093, 1992.

    Google Scholar 

  59. Geboers ADH, Debruyne FMJ: Surgery in advanced renal cell carcinoma. Contemp Urol 6 (6): 37–48, 1994.

    Google Scholar 

  60. Smith E, Kursh ED, Makley J, Resnick MI: Treatment of osseous metastases secondary to renal cell carcinoma. J Urol 148: 784–787, 1992.

    PubMed  CAS  Google Scholar 

  61. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of 283 consecutive patients with metastatic mela noma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907–913, 1994.

    Article  PubMed  CAS  Google Scholar 

  62. deKernion JB, Berry D: The diagnosis and treatment of renal cell carcinoma. Cancer 45: 1947–1956, 1980.

    PubMed  CAS  Google Scholar 

  63. McLaughlin JK, Silverman DT, Hsing AW, Ross RK, Schoenberg JB, Yu MC, Sternhagen A, Lynch CF, Blot WJ, Fraumeni JF Jr: Cigarette smoking and cancers of the renal pelvis and ureter. Cancer Res 52: 254–257, 1992.

    PubMed  CAS  Google Scholar 

  64. Ross RK, Pagnini-Hill A, Landolph J, Gerkins V, Henderson BE: Analgesics, cigarette smoking and other risk factors for cancer of the renal pelvis and ureter. Cancer Res 49: 1045–1048, 1989.

    PubMed  CAS  Google Scholar 

  65. Jensen OM, Knudsen JB, McLaughlin JK, Sorensen BL: The Copenhagen case-control study of renal pelvis and ureter cancer: role of smoking and occupational exposures. Cancer 41: 557–561, 1988.

    CAS  Google Scholar 

  66. McRedie M, Stewart JH, Day NE: Different role for phenacetin and paracetomol in cancer of the kidney and renal pelvis. Int J Cancer 53: 245–249, 1993.

    Article  Google Scholar 

  67. Lomax-Smith JD, Seymour AE: Neoplasia in analgesic nephropathy: a urothelial field change. Am J Surg Pathol 4: 565–572, 1980.

    Article  PubMed  CAS  Google Scholar 

  68. Richie JP: Carcinoma of the renal pelvis and ureter. In: DG Skinner, G Lieskovsky, eds, Genitourinary Cancer. WB Saunders Philadelphia, pp 323–336, 1988.

    Google Scholar 

  69. Catalona WJ: Urothelial tumors of the renal pelvis and ureter. In: PC Walsh, AB Retik, TA Stamey, ED Vaughn Jr, eds, Campbell’s Urology. WB Saunders, Philadelphia, pp 1137–1146, 1992.

    Google Scholar 

  70. Abdel-Razzak OM, Bagley D: Clinical experience with flexible ureteropyeloscopy. J Urol 148: 1788–1792, 1992.

    PubMed  CAS  Google Scholar 

  71. Bagley DH, Huffman JL, Lyon ES: Flexible ureteropyeloscopy: diagnosis and treatment in the upper urinary tract. J Urol 138: 280–285, 1987.

    PubMed  CAS  Google Scholar 

  72. Streem SB, Pontes EJ: Percutaenous management of upper tract transitional cell carcinoma. J Urol 135:773–775, J Urol 122: 163–164, 1979.

    Google Scholar 

  73. Corrado F, Mannini D, Ferri C, Corrado G, Bertoni F, Bacchini P, Lieber MRI, Song JM: The prognostic signifi cance of DNA ploidy pattern in transitional cell cancer of the renal pelvis and ureter: continuing follow-up. Eur Urol 21: 48–50, 1992.

    PubMed  Google Scholar 

  74. Babaian RJ: Primary carcinoma of the upper urinary tract epithelium: an overview. In: ED Crawford, S Das, ed, Current Genitourinary Cancer Surgery. Lea and Feiberger, Philadelphia, pp 88–96, 1990.

    Google Scholar 

  75. Mahadevia PS, Karwa GL, Koss LG: Mapping of urothelium in carcinomas of the renal pelvis and ureter. Cancer 51: 890–897, 1983.

    Article  PubMed  CAS  Google Scholar 

  76. Cummings KB: Nephroureterectomy: rationale in the management of transitional cell carcinoma of the upper urinary tract Urol Clin North Am 7: 569–578, 1980.

    PubMed  CAS  Google Scholar 

  77. Streem SB, Novick AC: How to plan for managing upper tract. tract TCC. Contemp Urol 4 (6): 41–54, 1992.

    Google Scholar 

  78. Cozad SC, Smalley SR, Austenfeld M, Noble M, Jennings S, Reymond R: Adjuvant radiotherapy in high stage transitional cell carcinoma of the renal pelvis and ureter. Int J Radiat Oncol Biol Phys 24: 743–745, 1992.

    Article  CAS  Google Scholar 

  79. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8: 1050–1055, 1990.

    PubMed  CAS  Google Scholar 

  80. Cancer Facts and Figures-1992. American Cancer Society, Atlanta GA, 1992.

    Google Scholar 

  81. Auerbach O, Garfinkel L: Histologic changes in the urinary bladder in relation to cigarette smoking and use of artificial sweeteners. Cancer 64: 983–987, 1989.

    Article  PubMed  CAS  Google Scholar 

  82. Wynder EL, Goldsmith R: The epidemiology of bladder cancer-a second look. Cancer 40: 1246–1268, 1977.

    Article  PubMed  CAS  Google Scholar 

  83. Kantor AF, Hartge P, Hoover RN, Fraumeni JF, Jr: Familial and environmental interactions in bladder cancer risk. Int J Cancer 35: 703–706, 1985.

    CAS  Google Scholar 

  84. Rehn L: Blasengeschwulste bei Fuchsin-Arbeitern. Arch Klin Chir 50: 588, 1895.

    Google Scholar 

  85. Shinka T, Sawada Y, Morimoto S, Fujinaga T, Nakamura J, Ohkawa T: Clinical study of urothelial tumors of dye workers in Wakayama City. J Urol 146: 1504–1507, 1991.

    PubMed  CAS  Google Scholar 

  86. Evans DAP, Manley KA, McKusick VA: Genetic control of isoniazid metabolism in man. Br Med J 2: 485–491, 1960.

    Article  PubMed  CAS  Google Scholar 

  87. Deguchi T, Mashimo M, Suzuki T: Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 265: 12757–12760, 1990.

    PubMed  CAS  Google Scholar 

  88. Ketterer B: Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat Res 202: 343–361, 1988.

    Article  PubMed  CAS  Google Scholar 

  89. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW: Genetic risk and carcinogen exposure: a com-mon inherited defect of the carcinogen-metabolism gene glutathione S-transferase Ml (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85: 1159–1164, 1993.

    Article  PubMed  CAS  Google Scholar 

  90. Piper JN, Matanoski GM, Tonascia T: Bladder cancer in young women. Am J Epidemiol 123: 1033–1042, 1986.

    PubMed  CAS  Google Scholar 

  91. Fairchild WV, Spence CR, Solomon HD, Gangai MP: The incidence of bladder cancer after cyclophosphamide therapy. 1986.

    Google Scholar 

  92. Kantor AF, Hartge P, Hoover RN, Fraumeni JF Jr: Epidemiologic characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res 48: 3853–3855, 1988.

    PubMed  CAS  Google Scholar 

  93. Miyao N, Tsai YC, Lerner SP, Olumi AF, Spruck CH III, Gonzalez-Zuleta M, Nichols PW, Skinner DG, Jones PA: Role of chromosome 9 in human bladder cancer. Cancer Res 53: 4066–4077, 1993.

    PubMed  CAS  Google Scholar 

  94. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, Dubeau L, Nichols PW, Hermann GG, Steven K, Horn T, Skinner DG, Jones PA: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 784–788, 1994.

    Google Scholar 

  95. Mostofi FK, Davis CJ Jr, Sesterhenn IA: Pathology of tumors of the urinary tract. In: DG Skinner, G Lieskovsky, eds, Diagnosis and Management of Genitourinary Cancer. WB Saunders, Philadelphia, pp 83–117, 1988.

    Google Scholar 

  96. Melicow MM: Tumors of the urinary drainage tract: urothelial tumors. J urol 54: 186–193, 1945.

    Google Scholar 

  97. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B: Clonal origin of bladder cancer. N Engl J Med 326: 737–740, 1992.

    Article  PubMed  CAS  Google Scholar 

  98. Marshall VF: Relation of preoperative estimate to pathologic demonstration of extent of vesical neoplasms. J Urol 68: 714723, 1952.

    Google Scholar 

  99. Skinner DG: Current state of classification and staging of bladder cancer. Cancer Res 37: 2838–2842, 1977.

    PubMed  CAS  Google Scholar 

  100. Heney NM: Natural history of superficial bladder cancer. Urol Clin North Am 19: 429–433, 1992.

    PubMed  CAS  Google Scholar 

  101. Hasui Y, Osada Y, Kitada S, Nishi S: Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer. Urology 43: 782–786, 1994.

    Article  PubMed  CAS  Google Scholar 

  102. Younes M, Sussman J, True LD: The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 66: 543548, 1990.

    Google Scholar 

  103. Lamm DL: Carcinoma in situ. Urol Clin North Am 19: 499508, 1992.

    Google Scholar 

  104. Amberson JB, Laino JP: Image cytometric deoxyribonucleic acid analysis of urine specimens as an adjunct to visual cytology in the detection of urothelial cell carcinoma. J Urol 149: 42–45, 1993.

    PubMed  CAS  Google Scholar 

  105. Murphy WM, Emerson LD, Chandler RW, Moinuddin SM, Soloway MS: Flow cytometry versus urinary cytology in the evaluation of patients with bladder cancer. J Urol 136: 815819, 1986.

    Google Scholar 

  106. Badalament RA, Kimmel M, Gay H, Cibas ES, Whitmore WF Jr, Fair WR, Melamed MR: The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial bladder cancer. Cancer 59: 2078–2085, 1987.

    Article  PubMed  CAS  Google Scholar 

  107. Bretton PR, Herr HW, Kimmel M, Fair WR, Whitmore WF Jr, Melamed MR: Flow cytometry as a predictor of response and progression in patients with superficial bladder cancer treated with Bacillus Calmette-Guerin. J Urol 141: 1332 1336, 1989.

    Google Scholar 

  108. Lamm DL: Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19: 573–580, 1992.

    PubMed  CAS  Google Scholar 

  109. Richie JP: Intravesical chemotherapy—treatment selection, techniques, and results. Urol Clin North Am 19: 521–527, 1992.

    PubMed  CAS  Google Scholar 

  110. Dalton JY, Wientjes MG, Badalament RA, Drago JR, Au JL-S: Pharmacokinetics of intravesical Mitomycin C in superficial bladder cancer patients. Cancer Res 51: 5144–5152, 1991.

    PubMed  CAS  Google Scholar 

  111. Garnick MB, Griffin JD, Sack MJ, Blum RM, Israel M, Frei EI: Phase II evaluation of N-trifluoracetyladriamycin-14valerate (AD-32). In: FM Muggia, CW Young, SK Carter, eds, Anthracycline Antibiotics in Cancer Therapy. Developments in Oncology, vol 10. Martinus Nijhoff, The Hague, pp 541–548, 1982.

    Google Scholar 

  112. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman B, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA: A randomizedtrial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205–1209, 1991.

    Article  PubMed  CAS  Google Scholar 

  113. Glashan RW: A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 144: 658–6661, 1990.

    PubMed  CAS  Google Scholar 

  114. Sarosdy MF, Lamm DL, Williams RD, Moon TD, Flanigan RC, Crawford ED, Wilks NE, Earhart RH, Merritt JA: Phase 1 trial of oral bropiramine in superficial bladder cancer. J Urol 147: 31–33, 1992.

    PubMed  CAS  Google Scholar 

  115. Skinner DG, Lieskovsky G: Management of invasive and high-grade bladder cancer. In: DG Skinner, G Lieskovsky, eds, Diagnosis and Management of Genitourinary Cancer. WB Saunders, Philadelphia, pp 295–312, 1988.

    Google Scholar 

  116. Lerner SP, Skinner E, Skinner DG: Radical cystectomy in regionally advanced bladder cancer. Urol Clin North Am 19: 713–724, 1992.

    PubMed  CAS  Google Scholar 

  117. Lerner SP, Skinner DG, Lieskovsky G, Boyd SD, Groshen SL, Ziogas A, Skinner E, Nichols P, Hopwood B: The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol 149: 758–765, 1993.

    PubMed  CAS  Google Scholar 

  118. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, Groshen S: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145: 459–467, 1991.

    PubMed  CAS  Google Scholar 

  119. Stockle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thuroff JW, Huber C, Hohenfellner R: Advanced bladder cancer (Stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 148: 302–307, 1992.

    PubMed  CAS  Google Scholar 

  120. Sternberg CN, Arena MG, Calabresi F, DeCarli P, Platania A, Zeuli M, Giannarelli D, Cancrini A, Pansadoro V: Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. Cancer 72: 1975–1982, 1993.

    Article  PubMed  CAS  Google Scholar 

  121. Scher HI, Kantoff PW: Chemotherapy for muscle-infiltrating bladder cancer. Hematol Oncol Clin North Am 6: 169–178, 1992.

    PubMed  CAS  Google Scholar 

  122. Van der Werf-Messing B: Cancer of the urinary bladder treated by interstitial radium implant. Int J Radiat Oncol Biol Phys 4: 373–378, 1978.

    Article  PubMed  Google Scholar 

  123. Wesson MF: Radiation therapy in advanced bladder cancer. Urol Clin North Am 19: 725–734, 1992.

    PubMed  CAS  Google Scholar 

  124. Miller LS: Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 39: 973–980, 1977.

    Article  PubMed  CAS  Google Scholar 

  125. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT: Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 329: 1377–1382, 1993.

    Article  PubMed  CAS  Google Scholar 

  126. Given RW, Wajsman Z: Bladder sparing multimodality treatment of muscle-invasive bladder cancer—a five year folow-up (abstract 901). J Urol 151: 453A, 1994.

    Google Scholar 

  127. Steinberg GD, Trump DL, Cummings KB: Metastatic bladder cancer—natural history, clinical course, and consideration for treatment. Urol Clin North Am 19: 735–746, 1992.

    PubMed  CAS  Google Scholar 

  128. Sternberg CN, Scher HI: Advances in the treatment of urothelial tract tumors. Urol Clin North Am 14: 373–387, 1987.

    PubMed  CAS  Google Scholar 

  129. Sternberg C, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, Morse MJ, Whitmore WF: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403–407, 1985.

    PubMed  CAS  Google Scholar 

  130. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weiselberg L, Rosado K, Smart T, Lin S-Y, Penenberg D, Fair WR, Whitmore WF Jr: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transtional cell carcinoma of the urothelium. Cancer 64: 2448–2458, 1989.

    Article  PubMed  CAS  Google Scholar 

  131. Harker GW, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, Torti FM: Cisplatin methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract-a Northern California Oncology Group Study. J Clin Oncol 3: 1463–1470, 1985.

    PubMed  CAS  Google Scholar 

  132. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA, Blumenstein B, Trump D: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10: 1066–1073, 1992.

    PubMed  Google Scholar 

  133. Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer RJ, O’Dell M, Curley T, Dershaw DD, Quinlivan S, Tao Y, Fair WR, Begg C, Bosl GJ: Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11: 408–414, 1993.

    PubMed  CAS  Google Scholar 

  134. Logothetis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU: Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicincisplatin plus unglycosylated recombinant human granulocytye-macrophage colony-stimulating factor. J Natl Cancer Inst 82: 667–672, 1990.

    Article  PubMed  CAS  Google Scholar 

  135. Bricker EM: Bladder substitution after pelvic evisceration. Surg Clin North Am 30: 1511–1521, 1950.

    CAS  Google Scholar 

  136. Gerber A: Improved quality of life following a Kock continent ileostomy. West J Med 133: 95–96, 1980.

    PubMed  CAS  Google Scholar 

  137. Boyd SD, Feinberg SM, Skinner DG, Lieskovsky G, Baron, D, Richardson J: Quality of life survey of urinary diversion patients: comparison of ileal conduits versus Kock ileal reservoirs. J Urol 138: 1386–1389, 1987.

    PubMed  CAS  Google Scholar 

  138. Jones MA, Breckman B, Hendry WF: Life with an ileal conduit: results of questionnaire surveys of patients and urological surgeons. Br J Urol 52: 21–25, 1980.

    Article  PubMed  CAS  Google Scholar 

  139. McLeod RS, Fazio VW: Quality of life with the continent ileostomy. World J Surg 8: 90–95, 1984.

    Article  PubMed  CAS  Google Scholar 

  140. Boyd SD, Lieskovsky G, Skinner DG: Kock pouch bladder replacement. Urol Clin North Am 18: 641–648, 1991.

    PubMed  CAS  Google Scholar 

  141. Stenzl A, Draxl H, Hernegger B, Bartsch G: Localization study of bladder cancer in the female: can urethral segments safely be spared at radical cytectomy? (abstract 989). J Urol 151: 475A, 1994.

    Google Scholar 

  142. Stein JP, Cote R, Freeman JA, Esrig D, Skinner EC, Boyd SD, Lieskovsky G, Skinner DG: Lower urinary tract reconstruction in women following cystectomy for pelvic malignancy: a pathological review of female cystectomy specimens (abstract 308). J Urol 151: 304A, 1994.

    Google Scholar 

  143. Esrig D, Elmajian D, Freeman JA, Nichols P, Groshen S, Chen S-C, Skinner DG, Jones P, Cote RJ: p53 nuclear accumulation and tumor progression in organ confined bladder cancer. (abstract 860). J Ural 151: 442A, 1994.

    Google Scholar 

  144. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang Z-F, Sheinfeld J, Fair WR, Herr HW, Reuter VE: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85: 53–59, 1993.

    Article  PubMed  CAS  Google Scholar 

  145. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang Z-F, Sheinfeld J, Fair WR, Herr HW, Reuter VE: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 152: 388–392, 1994.

    PubMed  CAS  Google Scholar 

  146. Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, Reuter VE: Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 84: 1251–1256, 1992.

    Article  PubMed  CAS  Google Scholar 

  147. Bringuier PP, Umbas R, Schaafsma E, Karthaus HFM, Debruyne, FMJ, Schalken JA: Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 53: 3241–3245, 1993.

    PubMed  CAS  Google Scholar 

  148. Jaeger TM, Weidner N, Chew K, Moore DH, Kerschmann RL, Waldman FM, Carroll PR: Tumor angiogenesis and lymph node metatasis in invasive bladder carcinoma (abstract 482). J Urol 151: 348A, 1994.

    Google Scholar 

  149. Nguyen M, Watanabe H, Budson AE, Richie JP, Folkman J: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 85: 241–242, 1993.

    Article  PubMed  CAS  Google Scholar 

  150. Seidman H, Mushinski MH, Gelb SK, Silverberg E: Probabilities of eventually developing or dying of cancer-United States, 1985. CA 35: 36–56, 1985.

    PubMed  CAS  Google Scholar 

  151. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC: Family history and the risk of prostate cancer. Prostate 17: 337–347, 1990.

    Article  PubMed  CAS  Google Scholar 

  152. Spitz MR, Currier RD, Fueger JJ, Babaian J, Newell GR: Familial patterns of prostate cancer: a case-control analysis. J Urol 146: 1305–1307, 1991.

    PubMed  CAS  Google Scholar 

  153. Carter BS, Bova S, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC: Hereditary prostate cancer: epidemiologic and clinical features. J Ural 150: 797–802, 1993.

    CAS  Google Scholar 

  154. SEER Program: Cancer Incidence and Mortality in the United States,1973–1981. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD, NIH Pub. No. 85–1837, 1984.

    Google Scholar 

  155. Coetzee GA, Ross, RK: Re: Prostate cancer and the androgen receptor. J Natl Cancer Inst 86: 872–873, 1994.

    Article  PubMed  CAS  Google Scholar 

  156. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FA, Pike MC, Henderson BE: 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339: 887–889, 1992.

    Article  PubMed  CAS  Google Scholar 

  157. Henchetnchette CL, Schwartz GG: Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70: 2861–2869, 1992.

    Article  Google Scholar 

  158. Gleason DF, Mellinger GT: The Veteran’s Administration Cooperative Urological Research Group: prediction of prognosis for prostatic carcinoma by combined histological grading and clinical staging. J Urol 111: 58–64, 1974.

    PubMed  CAS  Google Scholar 

  159. McNeal JE, Kindrachuk RA, Freiha FS, Bostwick DG, Redwine EA, Stamey TA: Patterns of progression in prostate cancer. Lancet 1: 60–63, 1986.

    Article  PubMed  CAS  Google Scholar 

  160. Watson RA, Tang DB: The predictive value of prostatic acid phosphatase as a screening test for prostatic cancer. N Engl J Med 303: 497–499, 1980.

    Article  PubMed  CAS  Google Scholar 

  161. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol 17:159163, 1979.

    Google Scholar 

  162. Hara M, Inorre T, Fukuyama T: Some physicochemical characteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma. Jpn J Leg Med 25: 32 2324, 1971.

    Google Scholar 

  163. Gerber GS, Chodak GW: Digital rectal examination in the early detection of prostate cancer. Urol Clin North Am 17: 739–744, 1990.

    CAS  Google Scholar 

  164. Chodak GW, Keller P, Schoenberg HW: Assessment of screening for prostate cancer using the digital rectal examination. J Urol 141: 1136–1138, 1989.

    PubMed  CAS  Google Scholar 

  165. Lee F, Littrup PJ, Torp-Pedersen ST, Mettlin C, McHugh TA, Gray JM, Kumasaka GH, McLeary RD: Prostate cancer: comparison of transrectal US and digital rectal examination for screening. Radiology 168: 389–394, 1988.

    PubMed  CAS  Google Scholar 

  166. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156–1161, 1991.

    Article  PubMed  CAS  Google Scholar 

  167. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147: 841–845, 1992.

    PubMed  CAS  Google Scholar 

  168. Hudson MA, Migliore P, Weinberg A, Hedrick T, Wargo M, Scardino PT: Use of digital rectal exam, transrectal ultrasonography and serum PSA in prostate cancer screening (abstract 676). J Urol 145: 381A, 1991.

    Google Scholar 

  169. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS: Screening for prostate cancer-a decision analytic view. JAMA 272: 773–780, 1994.

    Article  PubMed  CAS  Google Scholar 

  170. Fleming C, Wasson JH, Albertson PC, Barry MJ, Wennberg JE: A decision analysis of the treatment strategies for clinically localized prostate cancer. JAMA 269: 2650–2658, 1993.

    Article  PubMed  CAS  Google Scholar 

  171. Johansson J-E, Adami H-O, Andersson S-O, Bergstrom R, Holmberg L, Krusemo UB: High 10-year survival rate in patients with early, untreated prostate cancer. JAMA 267: 2191–2196, 1992.

    Article  PubMed  CAS  Google Scholar 

  172. Chodak GW, Thisted RA, Gerber GS, Johansson J-E, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J: Results of conservative management of clinically localized prostate cancer. N Engl J Med 330: 242–248, 1994.

    Article  PubMed  CAS  Google Scholar 

  173. Lerner SP, Seale-Hawkins C, Carlton CE Jr, Scardino PT: The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 146: 1040–1045, 1991.

    PubMed  CAS  Google Scholar 

  174. Whitmore WF Jr: Hormone therapy in prostate cancer. Am J Med 21: 697–713, 1956.

    Article  PubMed  Google Scholar 

  175. Shabsigh R, Carter SSC, Egawa S, Wright CD, Carlton CE Jr, Scardino PT: Transrectal ultrasound and/or digitial guided biopsy of the prostate. (abstract 449). J Urol 141: 282A, 1989.

    Google Scholar 

  176. Hodge KK, McNeal JE, Terris MK, Stamey TA: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142: 71–75, 1989.

    PubMed  CAS  Google Scholar 

  177. Scardino PT: The prognostic significance of acid phosphatase levels in the upper range of normal (abstract 356) J Urol 133: 202A, 1985.

    Google Scholar 

  178. Chybowski FM, Larson Keller JJ, Bergstralh EJ, Oesterling JE: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 145: 313–318, 1991.

    PubMed  CAS  Google Scholar 

  179. Gervasi LA, Mata JA, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE Jr, Scardino PT: Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 142: 332–336, 1989.

    PubMed  CAS  Google Scholar 

  180. Morton RA, Steiner MS, Walsh PC: Cancer control following anatomical radical prostatectomy. J Urol 145: 1197–1200, 1991.

    PubMed  CAS  Google Scholar 

  181. Carlton CE Jr, Scardino PT: Long-term results after combined radioactive gold seed implantation and external beam radiotherapy for localized prostatic cancer. In: DS Coffey, MI Resnick, FA Dorr, JP Karr, eds, A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. Plenum, New York, pp 109–121, 1988.

    Chapter  Google Scholar 

  182. Catalona WJ: Patient selection for, results of, and impact on tumor resection of potency-sparing radical prostatectomy. Urol Clin North Am 17: 819–826, 1990.

    PubMed  CAS  Google Scholar 

  183. Goad JR, Rogers E, Ohori M, Boone TB, Scardino PT: Incontinence after radical prostatectomy in 315 patients: the outcome and risk factors (abstract 1044). J Urol 151: 488A, 1994.

    Google Scholar 

  184. Fitzgerald KB, Goad JR, Collini P, Kassabian V, Scardino PT: Declining intraoperative blood loss during radical prostatectomy: is autologous blood donation necessary? (abstract 661). J Urol 149: 378A, 1993.

    Google Scholar 

  185. Lange PH, Lightner DJ, Medini E, Reddy PK, Vessella RL: The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol 144: 927–932, 1990.

    PubMed  CAS  Google Scholar 

  186. Schild SE, Wong WW, Grado GL, Buskirk SJ, Robinow JS, Frick LM, Ferrigni RG: Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc 69: 613–619, 1994.

    Article  PubMed  CAS  Google Scholar 

  187. Bagshaw MA: Radiation therapy for cancer of the prostate. In: DG Skinner, G Lieskovsky, eds, Diagnosis and Management of Genitourinary Cancer. WB Saunders, philadelphia, pp 425–445, 1988.

    Google Scholar 

  188. Lerner SP, Groshen SL, Seale-Hawkins C, Rogers E, Carlton CE Jr, Scardino PT: Fifteen year survival and recurrence rates after radiotherapy for localized prostate cancer (abstract 416). J Urol 145: 316A, 1991.

    Google Scholar 

  189. Whitmore WF Jr, Hilaris B, Sogani P, Herr H, Batata M, Rair W: Interstitial irradiation using I-125 seeds. Proc Clin Biol Res 243B: 177–195, 1987.

    Google Scholar 

  190. Denis L, Smith P, de Moura C, Newling D, Bono A, Keuppens F, Mahler C, Robinson M, Sylvester R, De Pauw M, Vermeylen K, Ongena P: Total androgen ablation: European experience. Urol Clin North Am 18: 65–73, 1991.

    PubMed  CAS  Google Scholar 

  191. Crawford ED, Nabors WL: Total androgen ablation: American experience. Urol Clin North Am 18: 55–64, 1991.

    PubMed  CAS  Google Scholar 

  192. Kuban DA, Schellhammer PF, El-Mandi AM: Hemibody irradiation in advanced prostatic carcinoma. Urol Clin North Am 18: 131–138, 1991.

    CAS  Google Scholar 

  193. LaRocca RV, Cooper MR, Uhrich M, Danesi R, Walther MM, Linehan WM, Meyers CE: Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin North Am 18: 123–130, 1991.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scott Department of Urology, Baylor College of Medicine, Houston, TX, 77030, USA

    Seth P. Lerner M.D. (Assistant Professor of Medicine) & James Eastham M.D.

Authors
  1. Seth P. Lerner M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Eastham M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Wadi N. Suki M.D. Shaul G. Massry M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lerner, S.P., Eastham, J. (1998). Cancers of the Urinary Tract. In: Suki, W.N., Massry, S.G. (eds) Suki and Massry’s THERAPY OF RENAL DISEASES AND RELATED DISORDERS. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6632-5_42

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-6632-5_42

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-6634-9

  • Online ISBN: 978-1-4757-6632-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation